Prevalence of overt myeloproliferative neoplasms and <i>JAK2</i> V617F mutation in Korean patients with splanchnic vein thrombosis

Yoo, Eun-Hyung; Jang, Jun Ho; Park, K.-J.; Gwak, Geum‐Youn; Kim, H.-J.; Kim, S.-H.; Kim, D.-K.

doi:10.1111/j.1751-553x.2011.01308.x

Cited by 11 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some patients the onset is presented with thrombus and bleeding. The prevalence of overt MPN and that of JAK2V617F mutation in Korean patients with splanchnic vein thrombosis (SVT) were lower than in previous reports 17 . The association between JAK2V617F mutation burden and clinical phenotype in Chinese patients is unknown.…”

Section: Introductioncontrasting

confidence: 55%

Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET)

Zhao¹,

Zhang²,

Xu³

et al. 2016

Int. J. Med. Sci.

View full text Add to dashboard Cite

Most patients with polycythemia vera (PV) and half of essential thrombocythemia (ET) possess an activating JAK2V617F mutation. The objective of this study was to better define the effect of JAK2V617F mutant allele burden on clinical phenotypes in Chinese patients, especially thrombosis. By real-time polymerase chain reaction (RT-PCR), the JAK2V617F mutation burden was detected in 170 JAK2V617F-positive patients, including 54 PV and 116 ET. The results showed that JAK2V617F allele burden was higher in PV than in ET (P< 0.001). Higher percentage of patients had JAK2V617F allele burden over 20% in PV than in ET (68.5% VS 26.7%) (P< 0.001). In PV patients, higher JAK2V617F allele burden was observed in female (P< 0.05) and leukocytosis patients (WBC above 10×109/L) (P< 0.001). Meanwhile, ET patients showed increased JAK2V617F allele burden in the group with higher hemoglobin (HGB above 150g/L) (P< 0.05), leukocytosis (WBC above 10×109/L) (P< 0.001), splenomegaly (P< 0.05) and thrombosis (P< 0.05). In conclusion, the JAK2V617F mutation allele burden is higher in Chinese patients with PV than ET. In PV patients, JAK2V617F mutation burden had influence on WBC counts. And the clinical characteristics of ET patients, such as WBC counts, hemoglobin level, splenomegaly and thrombosis, were influenced by JAK2V617F mutation burden. Male, high hemoglobin (HGB above 150g/L), and increased JAK2V617F mutation burden (JAK2V617F allele burden ≥16.5%) were risks of thrombosis (P< 0.05) for ET patients by Logistic Regression.

show abstract

Section: Introductioncontrasting

confidence: 55%

Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET)

Zhao¹,

Zhang²,

Xu³

et al. 2016

Int. J. Med. Sci.

View full text Add to dashboard Cite

show abstract

“…Of the 53 retrieved studies, 21 were excluded because of the following reasons: in 2 studies, patients with malignancies or liver cirrhosis were not excluded or explicitly mentioned 30,31 ; 5 studies were based on selected cohorts in which patients with established MPNs or other thrombophilic factors were excluded [32][33][34][35][36] ; one study did not differentiate SVT into BCS and PVT 37 ; in 4 studies, MPN criteria were not acceptable or unclear 14,[38][39][40] ; and 2 studies included Ͻ 10 patients. 29,41 In addition, 7 studies contained duplicate data.…”

Section: Study Identification and Selectionmentioning

confidence: 99%

Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis

Smalberg

Arends

Valla

et al. 2012

Blood

316

246

View full text Add to dashboard Cite

“…Hepatic Doppler ultrasound shows no or change in direction of blood flow (4). The onset of disease is variable and is dependent upon the speed of hepatic vein outflow occlusion (5). Polycythemia vera is a stem cell disease that is characterized by excess erythroid proliferation and is diagnosed using the WHO criteria, which is divided in major and minor criteria (6).…”

Section: Discussionmentioning

confidence: 99%

Budd-Chiari syndrome secondary to polycythemia vera with inferior vena cava thrombosis

Majid¹,

Tasneem²,

Luck³

et al. 2017

Immunopathol Persa

View full text Add to dashboard Cite

A middle aged male presented with abdominal distension since one month. Further workup showed plasma hemoglobin of 18.1 g/dL with a high pack cell volume (PCV), raised urea, creatinine and disturbed liver function tests. Abdominal ultrasonography showed an enlarged caudate lobe with thrombi in the inferior vena cava while CT scan of abdomen confirmed the same findings and was suggestive of Budd-Chiari syndrome. Further workup was conducted to rule out other causes and to find out the possible cause of Budd-Chiari syndrome. A peripheral film was requested, which showed hyper-segmented neutrophils. Later on JAK2 mutation and thrombophilia profile was ordered, which was positive for JAK2 mutation. Even though the patient was started on low molecular weight heparin but he eventually passed away.

show abstract

Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis

Abstract: The prevalence of overt MPN and that of JAK2 V617F were lower in Korean patients with SVT than in previous reports. Data from a larger number of patients with long-term follow-up are needed to reveal the clinical relevancy of JAK2 V617F in Korean patients with SVT.

Cited by 11 publications

References 33 publications

Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET)

Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET)

Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis

Budd-Chiari syndrome secondary to polycythemia vera with inferior vena cava thrombosis

Contact Info

Product

Resources

About